@article{discovery10143524,
       publisher = {John Wiley and Sons},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
           title = {Practical application of Alzheimer's Disease Neuroimaging Initiative plasma P-tau181 reference data to support diagnosis of Alzheimer's disease},
         journal = {International Journal of Geriatric Psychiatry},
            year = {2022},
           month = {February},
          volume = {37},
          number = {2},
        keywords = {Alzheimer's disease, biomarker, diagnosis, p-tau181},
             url = {https://doi.org/10.1002/gps.5670},
          author = {Hazan, Jemma and Alston, Duncan and Fox, Nick C and Howard, Robert},
        abstract = {OBJECTIVES: To assess plasma phosphorylated tau181 (p-tau181) levels in Alzheimer's disease (AD), cognitively impaired non-AD participants (CI non-AD) and Control participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset that could potentially act as reference data for clinic diagnoses of AD. METHODS: Data from 1558 participants (649 AD participants, 445 CI non-AD participants and 464 controls) were examined, comparing p-tau181 levels between Controls, AD and other dementias, stratified by age. RESULTS: There were significant differences in plasma p-tau181 values between Controls and those with AD at all ages up to 85�years. There were also significant differences between AD and CI non-AD participants up to the age of 85�years. CONCLUSIONS: Plasma P-tau181 may be a useful tool in the diagnosis of AD in those clinical settings where biomarkers have traditionally been less used. P-tau181 may be less useful as an aid to diagnosis in the very oldest-old. Further work is needed to establish the feasibility and utility of this biomarker within dementia diagnosis services not led by Neurologists, such as UK National Health Service Memory Services.}
}